D.A. Davidson & Co. Viking Therapeutics, Inc. Transaction History

D.A. Davidson & Co.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$4.6 - $6.72 $57,499 - $84,000	-12,500 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$5.19 - $6.73 $5,190 - $6,730	1,000 Added 8.7%	12,500 $75,000
Q1 2021 May 07, 2021	BUY	$5.74 - $9.67 $66,010 - $111,205	11,500 New	11,500 $73,000
Q4 2019 Feb 14, 2020	SELL	$6.38 - $8.73 $103,037 - $140,989	-16,150 Closed	0 $0
Q3 2019 Nov 05, 2019	SELL	$6.55 - $8.6 $982 - $1,290	-150 Reduced 0.92%	16,150 $111,000

Q2 2019 Aug 13, 2019	BUY	$7.67 - $10.63 $4,448 - $6,165	580 Added 3.69%	16,300 $135,000
Q1 2019 May 13, 2019	BUY	$7.58 - $9.94 $15,652 - $20,526	2,065 Added 15.12%	15,720 $156,000
Q4 2018 Jan 29, 2019	BUY	$7.16 - $16.21 $97,769 - $221,347	13,655 New	13,655 $104,000

426

63.1M

7.39M

5.13M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.87B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.